132 related articles for article (PubMed ID: 12415246)
1. Therapeutic strategies for Alzheimer's disease.
Wolfe MS
Nat Rev Drug Discov; 2002 Nov; 1(11):859-66. PubMed ID: 12415246
[TBL] [Abstract][Full Text] [Related]
2. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
3. Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.
Guix FX; Ill-Raga G; Bravo R; Nakaya T; de Fabritiis G; Coma M; Miscione GP; Villà-Freixa J; Suzuki T; Fernàndez-Busquets X; Valverde MA; de Strooper B; Muñoz FJ
Brain; 2009 May; 132(Pt 5):1335-45. PubMed ID: 19251756
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's disease therapeutics: new approaches to an ageing problem.
Small DH; Losic D; Martin LL; Turner BJ; Friedhuber A; Aguilar MI
IUBMB Life; 2004 Apr; 56(4):203-8. PubMed ID: 15230347
[TBL] [Abstract][Full Text] [Related]
5. Beyond amyloid: the next generation of Alzheimer's disease therapeutics.
Seabrook GR; Ray WJ; Shearman M; Hutton M
Mol Interv; 2007 Oct; 7(5):261-70. PubMed ID: 17932415
[TBL] [Abstract][Full Text] [Related]
6. [Fundamental data on the pathologies amyloid and Tau in Alzheimer's disease: which therapeutic perspectives?].
Checler F; Buée L
Ann Pharm Fr; 2009 Mar; 67(2):136-53. PubMed ID: 19298897
[TBL] [Abstract][Full Text] [Related]
7. Selection of peptides binding to the amyloid b-protein reveals potential inhibitors of amyloid formation.
Schwarzman AL; Tsiper M; Gregori L; Goldgaber D; Frakowiak J; Mazur-Kolecka B; Taraskina A; Pchelina S; Vitek MP
Amyloid; 2005 Dec; 12(4):199-209. PubMed ID: 16399644
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of oxidant mechanisms in Alzheimer's disease.
Moreira PI; Smith MA; Zhu X; Santos MS; Oliveira CR; Perry G
Expert Rev Neurother; 2004 Nov; 4(6):995-1004. PubMed ID: 15853526
[TBL] [Abstract][Full Text] [Related]
9. Amyloid inhibitors and Alzheimer's disease.
Xia W
Curr Opin Investig Drugs; 2003 Jan; 4(1):55-9. PubMed ID: 12625030
[TBL] [Abstract][Full Text] [Related]
10. The modulation of metal bio-availability as a therapeutic strategy for the treatment of Alzheimer's disease.
Crouch PJ; White AR; Bush AI
FEBS J; 2007 Aug; 274(15):3775-83. PubMed ID: 17617225
[TBL] [Abstract][Full Text] [Related]
11. [Advances in molecular biology and clinical study of amyloid precursor protein for Alzheimer's disease].
Xu BG; Wu X
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Apr; 26(2):201-9. PubMed ID: 15171563
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic approaches to Alzheimer's disease.
Klafki HW; Staufenbiel M; Kornhuber J; Wiltfang J
Brain; 2006 Nov; 129(Pt 11):2840-55. PubMed ID: 17018549
[TBL] [Abstract][Full Text] [Related]
13. Amyloid flirting with synaptic failure: towards a comprehensive view of Alzheimer's disease pathogenesis.
Marcello E; Epis R; Di Luca M
Eur J Pharmacol; 2008 May; 585(1):109-18. PubMed ID: 18377893
[TBL] [Abstract][Full Text] [Related]
14. Beta-amyloid pathology in the entorhinal cortex of rats induces memory deficits: implications for Alzheimer's disease.
Sipos E; Kurunczi A; Kasza A; Horváth J; Felszeghy K; Laroche S; Toldi J; Párducz A; Penke B; Penke Z
Neuroscience; 2007 Jun; 147(1):28-36. PubMed ID: 17499931
[TBL] [Abstract][Full Text] [Related]
15. The immune system, amyloid-beta peptide, and Alzheimer's disease.
Weksler ME; Gouras G; Relkin NR; Szabo P
Immunol Rev; 2005 Jun; 205():244-56. PubMed ID: 15882358
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics.
Masters CL; Cappai R; Barnham KJ; Villemagne VL
J Neurochem; 2006 Jun; 97(6):1700-25. PubMed ID: 16805778
[TBL] [Abstract][Full Text] [Related]
17. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
Padmanabhan J; Levy M; Dickson DW; Potter H
Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Alzheimer's disease: from pharmacology to a better understanding of disease pathophysiology.
Silvestrelli G; Lanari A; Parnetti L; Tomassoni D; Amenta F
Mech Ageing Dev; 2006 Feb; 127(2):148-57. PubMed ID: 16278007
[TBL] [Abstract][Full Text] [Related]
19. Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease.
Rodríguez-Rodríguez C; Sánchez de Groot N; Rimola A; Alvarez-Larena A; Lloveras V; Vidal-Gancedo J; Ventura S; Vendrell J; Sodupe M; González-Duarte P
J Am Chem Soc; 2009 Feb; 131(4):1436-51. PubMed ID: 19133767
[TBL] [Abstract][Full Text] [Related]
20. Muscarinic agonists as preventative therapy for Alzheimer's disease.
Beach TG
Curr Opin Investig Drugs; 2002 Nov; 3(11):1633-6. PubMed ID: 12476965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
